ADC conjugation, redefined. Explore a rapid 3-hour workflow that delivers precise, controlled antibody-drug conjugates for ...

The antibody-drug conjugate (ADC) field is advancing at an unprecedented pace, with groundbreaking innovations and soaring investment. A 33% rise in new drugs, a surge in clinical trials, and ...

Join experts from Premier Research, Ashley Herrick, PhD, Vice President, Oncology Program Strategy; and Jordan Curry, Senior Project Director, Oncology, for the live webinar on Thursday, January 29, ...

Adagene Inc. has announced a partnership with ConjugateBio Inc. to provide a proprietary antibody for the development of innovative bispecific antibody-drug conjugates (ADCs). Adagene's CEO ...

The antibody-drug conjugate (ADC) manufacturing landscape offers the potential to leverage significant opportunities for cancer treatment, but faces complex challenges. Nevertheless, the ADC market ...

RBC Capital Markets has initiated coverage on Pyxis Oncology Inc PYXS with an Outperform rating and a price target of $7. Last month, Pyxis Oncology acquired Apexigen Inc., focused on discovering and ...

– Single-Asset Focused Collaboration, License, and Option Agreement Combines Tubulis’ Differentiated ADC Platform Technologies with Gilead’s Oncology Research and Development Expertise – FOSTER CITY, ...

Synaffix, a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), licensed its ADC technology to BigHat Biosciences ...

In 1910, German scientist Paul Ehrlich introduced a groundbreaking concept to the world: chemical compounds could be engineered to interact with unique receptors on disease-causing cells while ...